文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌18F-PSMA-11显像的PET协议优化及阅片者间信度

Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer.
PubMed 文献 · EJNMMI Res · 2020-02-24

研究纳入44例患者随机分入2.0 ± 0.2或4.0 ± 0.4 MBq/kg剂量组,比较不同采集时间与时长及呋塞米对病灶显示的影响,另招募22例不用呋塞米者对照。4 MBq/kg组各重建图像图像质量评分中位数均高于2 MBq/kg组(p值<0.01);加用呋塞米使干扰评分降低1分(p = 0.01106);阅片者间信度κ值由0.78(95% CI,0.65-0.92)升至0.94(95% CI,0.87-1)。

要点

  • 4 MBq/kg组所有重建图像的图像质量评分中位数均高于2 MBq/kg组,p值<0.01。
  • 加用呋塞米使干扰评分降低1分(p = 0.01106),便于评估输尿管邻近病灶。
  • 阅片者间信度κ值由0.78(95% CI,0.65-0.92)升至0.94(95% CI,0.87-1),提示存在学习曲线。

核心结论

  • 结果提示4.0 ± 0.4 MBq/kg的给药活度,但因绝对评分差异小(最大1分)及ALARA原则,更倾向于选择2.0 ± 0.2 MBq/kg。
  • 评估输尿管邻近病灶时,联合使用利尿剂可能有帮助。
  • κ值由0.78升至0.94提示18F-PSMA-11图像判读存在学习曲线。

研究设计与样本

  • 44例患者随机分入2.0 ± 0.2或4.0 ± 0.4 MBq/kg 18F-PSMA-11剂量组,注射后1 h和3 h行全身PET/CT,扫描时长3 min/床位,并按1.5和3 min/床位重建图像。
  • 患者静脉给予0.5 mg/kg呋塞米,最大剂量40 mg;另招募22例额外患者,给予2.0 ± 0.2 MBq/kg 18F-PSMA-11后1 h行全身PET/CT,扫描时长3 min/床位,不使用呋塞米。
  • 图像采用7分制评分评估图像质量,两名核医学医师独立评分所有扫描并描述所有可疑病灶以评估阅片者间信度。
  • 试验注册号NCT03573011,于2018年6月28日回顾性注册。

主要发现

  • 4 MBq/kg组在所有重建图像(注射后60 min的1.5和3 min/床位、注射后180 min的1.5和3 min/床位)的图像质量评分中位数均高于2 MBq/kg组,p值<0.01。
  • 比较所有重建图像时,两剂量组图像质量评分最高者均为注射后60 min、3 min/床位的图像(2和4 MBq/kg组评分分别为5和6)。
  • 加用呋塞米使干扰评分降低1分(p = 0.01106),并便于评估输尿管邻近病灶。
  • 超过40次18F-PSMA-11扫描判读后,逐病灶比较的阅片者间信度κ值由0.78(95% CI,0.65-0.92)升至0.94(95% CI,0.87-1)。

关键数值与推荐

  • 图像质量采用7分制评分。
  • 4 MBq/kg组所有重建图像图像质量评分中位数高于2 MBq/kg组,p值<0.01。
  • 注射后60 min、3 min/床位图像评分:2 MBq/kg组为5分,4 MBq/kg组为6分。
  • 加用呋塞米使干扰评分降低1分(p = 0.01106)。
  • 阅片者间信度κ值由0.78(95% CI,0.65-0.92)升至0.94(95% CI,0.87-1)。

临床怎么用

  • 作者认为,尽管结果提示4.0 ± 0.4 MBq/kg的给药活度,但因绝对评分差异小(最大1分)及ALARA原则,更倾向于选择2.0 ± 0.2 MBq/kg。
  • 作者认为,评估输尿管邻近病灶时,联合使用利尿剂可能有帮助。
  • 作者认为,κ值由0.78升至0.94提示18F-PSMA-11图像判读存在学习曲线。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg 18F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3 min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg. To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after administration of 2.0 ± 0.2 MBq/kg 18F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and described all observed suspicious lesions. RESULTS: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180 min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group (p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion separately after more than 40 18F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65-0.92) to 0.94 (95% CI, 0.87-1). CONCLUSION: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to 2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of 18F-PSMA-11 images. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Piron S, De Man K, Schelfhout V, et al. Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer. EJNMMI Res. 2020. PMID: 32095919. doi:10.1186/s13550-020-0593-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。